Neurology · Memphis area, TN
Neurology studies in Memphis area, TN
26 recruiting studies have a site in the Memphis area. This page includes nearby cities such as Germantown, Collierville, Cordova, Bartlett.
26 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
AbbVie
- Location
- Memphis, TN + 17 other US sites
- Eligibility basics
- Ages 18–85
- Recruiting
Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
RapidPulse, Inc
- Location
- Memphis, TN + 12 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Cordova, TN + 24 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Cordova, TN + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Memphis, TN + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Alpha Cognition, Inc
- Location
- Cordova, TN + 21 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
Pfizer
- Location
- Memphis, TN + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Cordova, TN + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Grifols Therapeutics LLC
- Location
- Cordova, TN + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
Aspeya, Inc.
- Location
- Memphis, TN + 19 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Cordova, TN + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Cordova, TN + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Memphis, TN + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Memphis, TN + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 4
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Genentech, Inc.
- Location
- Cordova, TN + 3 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Chattanooga, TN + 41 other US sites
- Eligibility basics
- Ages 12+
- Recruiting
MMA Embolization for Refractory Chronic Migraine
Cerenovus, Part of DePuy Synthes Products, Inc.
- Location
- Memphis, TN + 7 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Memphis, TN + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Cordova, TN + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
AbbVie
- Location
- Cordova, TN + 10 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Memphis, TN + 4 other US sites
- Eligibility basics
- Ages 2–12
- RecruitingPhase 3
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
Praxis Precision Medicines
- Location
- Memphis, TN + 5 other US sites
- Eligibility basics
- Ages 0 mo–18
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Chattanooga, TN + 69 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 1/Phase 2
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
AC Immune SA
- Location
- Cordova, TN + 3 other US sites
- Eligibility basics
- Ages 35–85
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.